IGF::OT::IGF OTHER FUNCTIONS RandD- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$197,224.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
N43CO120078
Agency Tracking Number:
N43CO120078
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
HUMANETICS CORPORATION
1550 UTICA AVE. S., SUITE 770, MINNEAPOLIS, MN, 55416
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
197085517
Principal Investigator:
MICHAEL KAYTOR
(952) 400-0404
MKAYTOR@HUMANETICSCORP.COM
Business Contact:
MICHAEL KAYTOR
(952) 400-0404
MKAYTOR@HUMANETICSCORP.COM
Research Institution:
Stub




Abstract
Lung cancer is the most common cause of cancer-related deaths in the United States. Humanetics will develop BIO 300 as a drug that can be given with radiotherapy for lung cancer to help improve efficacy and to decrease toxicity. The focus of the development will be with non-small cell lung cancers where BIO 300 has already shown an ability to inhibit cancer growth. BIO 300 also has a demonstrated ability to protect normal tissues exposed to radiation. In Phase I of this proposal, we will complete a series of mouse efficacy studies assessing BIO 300 s ability to inhibit tumor growth in an A549 xenograft non-small cell lung cancer model as well as evaluating the effects on normal tissues. In Phase II we will use the research results of the Phase I experiments along with the existing BIO 300 safety data to file an IND for the use of BIO 300 in patients receiving radiotherapy for non-small cell tumors of the lung. Once FDA clearance is obtained we will proceed with a clinical study to assess the safety andeffect of BIO 300 in improving the morbidity and mortality in patients receiving radiation therapy for non-small cell lung cancer.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government